Foghorn up as Eli Lilly picks its cancer therapy for development
08/02/2024 13:44
** Shares of therapy developer Foghorn Therapeutics FHTX.O
rise 14.75% to $3.58 premarket
** Co says Eli Lilly LLY.N has selected its therapy
FHD-909 for development for patients with a type of lung cancer
** LLY plans to file its application to start trials in Q2
** In Dec 2021, the companies announced a co-development and
co-commercialization agreement for cancer drugs using FHTX's
gene traffic control platform
** As of last close, FHTX stock has fallen ~61% in the last
12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))